Caris Life Sciences, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Caris Life Sciences reported Q2 2026 revenue of $263.7M (45% YoY growth) driven by 59,200 clinical cases and raised full-year 2026 revenue guidance to $1.03-$1.04B (27-28% growth vs. 2025). Gross margin improved 500 bps to 68%, company achieved net loss of only $0.6M vs. $71.8M loss prior year, and generated $28.5M operating cash flow. CEO highlighted launches of Caris Detect early-detection blood test and Caris ChromoSeq, plus announced $100M share repurchase program ($82.1M remaining).
Why this rating
Strong guidance raise (27-28% FY growth) and dramatic profitability swing ($71.8M loss→$0.6M) on ~$3.9B market cap is material. Revenue scale approaching $1B+ validates commercial model. Offset by modest absolute Q2 margin and cash burn on $100M buyback.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.